{3-[3-methyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amine | 854774-84-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: {3-[3-methyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amine
• 英文别名: 3-[3-Methyl-8-(trifluoromethyl)quinolin-4-yl]aniline
• CAS: 854774-84-8
• 化学式: C₁₇H₁₃F₃N₂
• 分子量: 302.299
• InChiKey: JOTVUDPBYMZUCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {3-[3-methyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amine 在 lithium hydroxide 、 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 反应 2.0h， 生成 2-{4-[({3-[3-Methyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl}acetic acid
  参考文献：
  名称：

  Further modification on phenyl acetic acid based quinolines as liver X receptor modulators

  摘要：

  A series of phenyl acetic acid based quinolines was prepared as LXR modulators. An SAR study in which the C-3 and C-8 positions of the quinoline core were varied led to the identification of two potent LXR agonists 23 and 27. Both compounds displayed good binding affinity for LXR beta and LXR alpha, and increased expression of ABCAl in THP-1 cells. These two compounds also had desirable pharmacokinetic profiles in mice and displayed in vivo efficacy in a 12-week Apo E knockout mouse lesion model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.013
• 作为产物：
  描述：

  邻氨基三氟甲苯 在 四(三苯基膦)钯 diphenyl ether-biphenyl eutectic 、 sodium hydride 、 sodium carbonate 、 三溴氧磷 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 2.0h， 生成 {3-[3-methyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amine
  参考文献：
  名称：

  Further modification on phenyl acetic acid based quinolines as liver X receptor modulators

  摘要：

  A series of phenyl acetic acid based quinolines was prepared as LXR modulators. An SAR study in which the C-3 and C-8 positions of the quinoline core were varied led to the identification of two potent LXR agonists 23 and 27. Both compounds displayed good binding affinity for LXR beta and LXR alpha, and increased expression of ABCAl in THP-1 cells. These two compounds also had desirable pharmacokinetic profiles in mice and displayed in vivo efficacy in a 12-week Apo E knockout mouse lesion model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.013

文献信息

• Quinolines useful in treating cardiovascular disease
  申请人：Collini D. Michael

  公开号：US20050131014A1

  公开（公告）日：2005-06-16

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了式I化合物的用途，它们在治疗或抑制LXR介导的疾病中是有用的。
• QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE
  申请人：Wyeth, A Corporation of the State of Delaware

  公开号：EP1692111A2

  公开（公告）日：2006-08-23
• JP2007516258A
  申请人：——

  公开号：JP2007516258A

  公开（公告）日：2007-06-21
• US7576215B2
  申请人：——

  公开号：US7576215B2

  公开（公告）日：2009-08-18
• [EN] QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE<br/>[FR] QUINOLINES CONVENANT POUR LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES
  申请人：WYETH CORP

  公开号：WO2005058834A2

  公开（公告）日：2005-06-30

  This invention provides compounds of formula (I) that are useful in the treatment or inhibition of LXR mediated diseases.